Apalutamide
- Generic Name
- Apalutamide
- Brand Names
- Erleada
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15F4N5O2S
- CAS Number
- 956104-40-8
- Unique Ingredient Identifier
- 4T36H88UA7
- Background
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Ne...
- Indication
Apalutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- Androgen Deprivation Therapy
BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
- Conditions
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 311
- Registration Number
- NCT03371719
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Therapeutics in Active Prostate Cancer Surveillance
- First Posted Date
- 2017-12-07
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- CCTU- Cancer Theme
- Target Recruit Count
- 11
- Registration Number
- NCT03365297
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust/Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT03360721
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
- Conditions
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Andrew J. Armstrong, MD
- Target Recruit Count
- 39
- Registration Number
- NCT03311555
- Locations
- 🇺🇸
GU Research Network / Urology Cancer Center, Omaha, Nebraska, United States
🇺🇸Weill Cornell Medical Center, New York, New York, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 28
- Registration Number
- NCT03298087
- Locations
- 🇺🇸
VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States
🇺🇸VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT03279250
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
- Conditions
- Interventions
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- University of Athens
- Registration Number
- NCT03173859
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 345
- Registration Number
- NCT03141671
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03124433
- Locations
- 🇸🇬
Department of Urology, Singapore, Singapore
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT03093272
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.